MX2021012418A - Compuestos heterociclicos y sus usos. - Google Patents

Compuestos heterociclicos y sus usos.

Info

Publication number
MX2021012418A
MX2021012418A MX2021012418A MX2021012418A MX2021012418A MX 2021012418 A MX2021012418 A MX 2021012418A MX 2021012418 A MX2021012418 A MX 2021012418A MX 2021012418 A MX2021012418 A MX 2021012418A MX 2021012418 A MX2021012418 A MX 2021012418A
Authority
MX
Mexico
Prior art keywords
heterocyclic compounds
compounds
find
oncology
diseases
Prior art date
Application number
MX2021012418A
Other languages
English (en)
Inventor
Sarvajit Chakravarty
Son Minh Pham
Brahmam Pujala
Jayakanth Kankanala
Sanjeev Soni
Puja Jaiswal
Deepak Palve
Varun Kumar
Original Assignee
Nuvation Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvation Bio Inc filed Critical Nuvation Bio Inc
Publication of MX2021012418A publication Critical patent/MX2021012418A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan compuestos heterocíclicos como inhibidores de Wee1; los compuestos pueden encontrar uso como agentes terapéuticos para el tratamiento de enfermedades y pueden encontrar uso particular en oncología.
MX2021012418A 2019-04-09 2020-04-08 Compuestos heterociclicos y sus usos. MX2021012418A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962831665P 2019-04-09 2019-04-09
PCT/US2020/027297 WO2020210375A1 (en) 2019-04-09 2020-04-08 Heterocyclic compounds and uses thereof

Publications (1)

Publication Number Publication Date
MX2021012418A true MX2021012418A (es) 2021-11-12

Family

ID=72748693

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012418A MX2021012418A (es) 2019-04-09 2020-04-08 Compuestos heterociclicos y sus usos.

Country Status (14)

Country Link
US (2) US11332473B2 (es)
EP (1) EP3952877A4 (es)
JP (1) JP2022526831A (es)
KR (1) KR20210150476A (es)
CN (1) CN113939296A (es)
AU (1) AU2020271837A1 (es)
BR (1) BR112021019703A2 (es)
CA (1) CA3136492A1 (es)
CL (1) CL2021002521A1 (es)
EA (1) EA202192746A1 (es)
IL (1) IL287026A (es)
MX (1) MX2021012418A (es)
SG (1) SG11202110615TA (es)
WO (1) WO2020210375A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019074979A1 (en) 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
CN117616029A (zh) * 2021-07-05 2024-02-27 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的稠环化合物
CN117751122A (zh) * 2021-08-11 2024-03-22 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物
WO2023045942A1 (zh) * 2021-09-22 2023-03-30 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2472835A1 (en) 2002-01-18 2003-07-31 Kyorin Pharmaceutical Co., Ltd. Fused bicyclic pyrimidine derivatives
CA2525383C (en) 2003-06-06 2012-03-06 Arexis Ab Use of heterocyclic compounds as scce inhibitors
US7205296B2 (en) 2004-09-29 2007-04-17 Portola Pharmaceuticals, Inc. Substituted 2H-1,3-benzoxazin-4(3H)-ones
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
RU2010101052A (ru) 2007-06-15 2011-07-20 Банью Фармасьютикал Ко., Лтд (Jp) Производные бициклоанилина
CA2703489A1 (en) * 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
JP2012511501A (ja) 2008-12-12 2012-05-24 Ｍｓｄ株式会社 ジヒドロピリミドピリミジン誘導体
PT2477628E (pt) 2009-09-15 2014-11-25 Merck Sharp & Dohme Preparação de formas de hemihidrato cristalino de dihidropirazolopirimidinona
WO2013013031A1 (en) 2011-07-19 2013-01-24 Abbvie Inc. Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
EP2776434A1 (en) 2011-10-20 2014-09-17 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
WO2013126656A1 (en) 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
PL2925888T3 (pl) 2012-11-28 2018-03-30 Merck Sharp & Dohme Corp. Kompozycje i sposoby do stosowania w leczeniu nowotworów
GB201306610D0 (en) 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
WO2015019037A1 (en) 2013-08-05 2015-02-12 Almac Discovery Limited Pharmaceutical compounds
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
EP3368538B1 (en) 2015-11-01 2021-09-01 The Regents of The University of Colorado, A Body Corporate Wee 1 kinase inhibitors and methods of making and using the same
GB201612095D0 (en) 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
GB201612092D0 (en) 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
KR102030886B1 (ko) 2016-09-23 2019-10-10 재단법인 대구경북첨단의료산업진흥재단 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
JP7240784B2 (ja) 2016-11-16 2023-03-16 上海瑛派▲薬▼▲業▼有限公司 ８，９－ジヒドロイミダゾール［１，２－ａ］ピリミド［５，４－ｅ］ピリミジン－５（６Ｈ）－ケトン類化合物
JP6717457B2 (ja) 2017-01-23 2020-07-01 シージャーズォアン サガシティ ニュー ドラッグ デベロップメント カンパニー リミテッド Ｗｅｅ１阻害剤としての１，２−ジヒドロ−３Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−３−オン誘導体
GB201703881D0 (en) 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
JP7140337B2 (ja) * 2017-03-23 2022-09-21 シャンハイ ドーァ ノボ ファーマテック カンパニー，リミティド ピラゾロ［３，４－ｄ］ピリミジン－３－オンの大環状誘導体、その医薬組成物及び応用
WO2018183891A1 (en) 2017-03-31 2018-10-04 Cascadian Therapeutics Combinations of chk1- and wee1 - inhibitors
WO2019011228A1 (zh) 2017-07-10 2019-01-17 上海瑛派药业有限公司 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
CN111094253B (zh) * 2017-08-01 2023-08-29 里科瑞尔姆Ip控股有限责任公司 1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮类似物
WO2019037678A1 (zh) 2017-08-24 2019-02-28 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
AU2018347307A1 (en) 2017-10-09 2020-04-23 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2019074979A1 (en) 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
WO2019096322A1 (zh) 2017-11-20 2019-05-23 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
CN111315747B (zh) 2018-01-05 2023-05-02 四川科伦博泰生物医药股份有限公司 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
WO2019165204A1 (en) * 2018-02-23 2019-08-29 Newave Pharmaceutical Inc. 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidine-3-one compounds as inhibitors of wee-1 kinase
WO2019169065A2 (en) 2018-02-28 2019-09-06 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of treating cancer using the same
IL276802B2 (en) 2018-03-09 2023-09-01 Recurium Ip Holdings Llc Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidine-3-ones
EP3952876A4 (en) 2019-04-09 2023-04-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
EP3952879A4 (en) 2019-04-09 2023-01-04 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
EP3952878A4 (en) 2019-04-09 2023-01-04 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
US20220220115A1 (en) 2019-04-09 2022-07-14 Nuvation Bio Inc. Heterocyclic compounds and uses thereof

Also Published As

Publication number Publication date
CA3136492A1 (en) 2020-10-15
IL287026A (en) 2021-12-01
SG11202110615TA (en) 2021-10-28
WO2020210375A1 (en) 2020-10-15
JP2022526831A (ja) 2022-05-26
EA202192746A1 (ru) 2021-12-29
US20230118115A1 (en) 2023-04-20
BR112021019703A2 (pt) 2021-12-14
AU2020271837A1 (en) 2021-11-18
EP3952877A4 (en) 2022-12-14
KR20210150476A (ko) 2021-12-10
CL2021002521A1 (es) 2022-04-29
US20200325142A1 (en) 2020-10-15
CN113939296A (zh) 2022-01-14
EP3952877A1 (en) 2022-02-16
US11332473B2 (en) 2022-05-17

Similar Documents

Publication Publication Date Title
AU2018347307A1 (en) Heterocyclic compounds and uses thereof
MX2020008559A (es) Compuestos heterocíclicos como inhibidores de la quinasa.
MX2020006128A (es) Inhibidores de la proteina de activacion de fibroblastos.
MX2021008342A (es) Derivados de pirazol como inhibidores de calicreina plasmatica.
MX2021012418A (es) Compuestos heterociclicos y sus usos.
MX2022000711A (es) Inhibidores de parp1.
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
MX2019002303A (es) Inhibidores de procesos metabolicos celulares.
PH12017500901A1 (en) N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors,
NZ735998A (en) Heterocyclic compounds as lsd1 inhibitors
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
PH12015502549B1 (en) Heterocyclic derivatives
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
ZA201904522B (en) Heterocyclic inhibitors of mct4
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
EP2576549A4 (en) Bicyclic Heteroarylkinase Inhibitors and Methods of Use
WO2020132661A3 (en) Inhibitors of fibroblast activation protein
MX2022001004A (es) Inhibidores de enzimas.
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
MX2017012123A (es) Combinaciones de un compuesto inhibidor de fosfoinositido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cancer.
MX2021007948A (es) Inhibidores de proteina de activacion de fibroblastos.
MX2022000811A (es) Inhibidores de enzimas.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX2022002069A (es) Inhibidores de enzimas.
ZA202106519B (en) Caspase inhibitors and methods of use thereof